Llwytho...
Reappraising antiangiogenic therapy for breast cancer
Phase III trials of antiangiogenic drugs for metastatic breast cancer have either had only limited success, e.g. the monoclonal anti-VEGF antibody bevacizumab when used with various conventional chemotherapy regimens, or have failed altogether, e.g. the small molecule oral tyrosine kinase inhibitor...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Breast |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2011
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540338/ https://ncbi.nlm.nih.gov/pubmed/22015294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(11)70295-8 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|